title: Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
abstract: Acute heart failure (AHF) remains a major cause of morbidity and mortality, with an increasing prevalence anticipated over the next few decades as the population ages, heightening already significant health and economic burdens to society. New therapies for AHF have stalled over the past decade for a multitude of reasons, principal among them the heterogeneous population of patients affected with potentially multiple operative pathophysiologic mechanisms making a single targeted therapy a challenge. Serelaxin, a recombinant form of human relaxin-2, mediates adaptive cardiovascular effects during pregnancy that could be beneficial in the AHF population, primarily through nitric oxide-mediated vasodilation. Serelaxin is a novel therapeutic agent that has shown promise in the treatment of AHF in predefined subpopulations, though studies powered for "hard" outcomes are still pending. In this review, we examine the clinical investigations to date involving serelaxin in patients with heart failure and its possible emerging role in the future therapy of AHF.
authors.affiliation: Division of Cardiology, Columbia University Medical Center, New York, NY, USA, bcv2103@columbia.edu.
authors.forename: Brandon C
authors.initials: BC
authors.lastname: Varr
authors.forename: Mathew S
authors.initials: MS
authors.lastname: Maurer
mesh_terms: D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D012065:Relaxin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D011994:Recombinant Proteins; C577649:serelaxin protein, human; D012065:Relaxin
references.citation: N Engl J Med. 2010 Oct 7;363(15):1419-28
references.pmid: 20925544
references.citation: J Clin Endocrinol Metab. 1991 Apr;72(4):899-904
references.pmid: 2005217
references.citation: JAMA. 2011 Oct 19;306(15):1669-78
references.pmid: 22009099
references.citation: Circ Heart Fail. 2010 Mar;3(2):314-25
references.pmid: 20233993
references.citation: J Am Coll Cardiol. 2009 Oct 27;54(18):1695-702
references.pmid: 19850209
references.citation: N Engl J Med. 2011 Mar 3;364(9):797-805
references.pmid: 21366472
references.citation: Lancet. 2013 Jan 5;381(9860):5-6
references.pmid: 23141815
references.citation: J Am Coll Cardiol. 2003 Mar 19;41(6):997-1003
references.pmid: 12651048
references.citation: J Am Heart Assoc. 2014 Feb 28;3(1):e000493
references.pmid: 24584737
references.citation: J Am Soc Nephrol. 2006 Nov;17(11):3192-7
references.pmid: 17035617
references.citation: Science. 2002 Jan 25;295(5555):671-4
references.pmid: 11809971
references.citation: Regul Pept. 2005 Dec 15;132(1-3):41-6
references.pmid: 16229906
references.citation: JACC Heart Fail. 2013 Apr;1(2):103-11
references.pmid: 24621834
references.citation: Int J Endocrinol Metab. 2014 Apr 01;12(2):e14098
references.pmid: 24803942
references.citation: FASEB J. 2014 Jan;28(1):275-87
references.pmid: 24036884
references.citation: Endocr Rev. 2004 Apr;25(2):205-34
references.pmid: 15082520
references.citation: Kidney Int. 1998 Dec;54(6):2056-63
references.pmid: 9853271
references.citation: Curr Hypertens Rep. 2011 Dec;13(6):409-20
references.pmid: 21971830
references.citation: JACC Heart Fail. 2014 Feb;2(1):24-31
references.pmid: 24622115
references.citation: Am Heart J. 2005 Feb;149(2):209-16
references.pmid: 15846257
references.citation: Circulation. 2011 Mar 1;123(8):933-44
references.pmid: 21262990
references.citation: J Am Coll Cardiol. 2013 Jan 15;61(2):196-206
references.pmid: 23273292
references.citation: Lancet. 2009 Apr 25;373(9673):1429-39
references.pmid: 19329178
references.citation: J Card Fail. 2009 Apr;15(3):182-90
references.pmid: 19327619
references.citation: Circ Res. 2003 Jan 10;92(1):32-40
references.pmid: 12522118
references.citation: Circulation. 2014 Jan 21;129(3):e28-e292
references.pmid: 24352519
references.citation: Lancet. 2013 Jan 5;381(9860):29-39
references.pmid: 23141816
references.citation: Eur J Heart Fail. 2013 Oct;15(10):1082-94
references.pmid: 23787718
references.citation: J Am Coll Cardiol. 2013 Jan 29;61(4):391-403
references.pmid: 23219302
references.citation: Hypertension. 2011 Jun;57(6):1151-60
references.pmid: 21536992
references.citation: Eur Heart J. 2013 Oct;34(40):3128-36
references.pmid: 23999454
references.citation: Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):259-68
references.pmid: 24594552
references.citation: Endocrinology. 2011 Jul;152(7):2786-96
references.pmid: 21558316
references.citation: Am J Physiol Regul Integr Comp Physiol. 2011 Aug;301(2):R267-75
references.pmid: 21613576
references.citation: J Am Coll Cardiol. 2009 Jun 16;53(24):2248-58
references.pmid: 19520247
references.citation: Eur Heart J. 2014 Feb;35(7):431-41
references.pmid: 24255129